Artificial intelligence company, Renalytix AI’s (LON: RENX) London-listed shares are climbing on Tuesday after the company and DaVita (NYSE: DVA) revealed they will be partnering on a program aimed at slowing disease progression and improving health outcomes for the 37 million adults in the US who suffer from chronic kidney disease (CKD).
Renalytix’s shares are trading at highs of 640p, up 16.36% on the day.
The program is expected to improve patient outcomes and provide meaningful cost reductions for health care providers and payors by enabling earlier intervention for patients with early-stage kidney disease through actionable risk assessments and end-to-end care management.
Ready to put what you’ve learned into practice?
Try IG’s platform with £10,000 in virtual funds and practise trading
without putting your own money at risk.
Try IG with a demo account →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Learn the markets with IG Academy
Build your knowledge with IG Academy educational content, then use a
demo account to practise what you’ve learned on the IG platform.
Explore IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
See how trading works before risking real money
IG’s demo gives you access to thousands of markets and £10,000 in
virtual funds, so you can explore the platform and test your ideas first.
Open an IG demo →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Turn trading theory into practical experience
Learn with IG Academy, explore charts and market tools, and practise
strategies in a simulated trading environment before going live.
Start practising with IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Ready to take your learning further?
IG combines market education, analysis and an established trading platform,
giving you the tools to keep learning as you develop your trading skills.
Discover IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
The companies said they expect to launch the collaboration in three markets this year.
“Almost 50% of people whose kidneys fail find out after it is too late, and we are on a mission to change that,” said Javier Rodriguez, CEO for DaVita.
“Our partnership with RenalytixAI could allow us to help slow disease progression for the millions of people living with kidney disease,” added Rodriguez.
The program will use the KidneyIntelX in vitro diagnostic platform from RenalytixAI, which uses a machine-learning algorithm to assess a combination of biomarkers. The initial version of the KidneyIntelX risk score identifies Type 2 diabetic patients with early-stage CKD.
“This is the first clinical-grade program that delivers advanced early-stage prognosis and risk stratification, combined with actionable care management right to the primary care level where the majority of kidney disease patients are being seen,” said James McCullough, Renalytix’s CEO.
